Review





Similar Products

psb 603  (MedChemExpress)
94
MedChemExpress psb 603
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb 603, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB-603/pmc13121447-44-12-14
Average 94 stars, based on 1 article reviews
psb 603 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
psb603  (Tocris)
94
Tocris psb603
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb603, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pm41506868-225-3-11
Average 94 stars, based on 1 article reviews
psb603 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
psb 603  (Tocris)
94
Tocris psb 603
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb 603, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pmc12910660-180-3-11
Average 94 stars, based on 1 article reviews
psb 603 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
a2br antagonist 8  (Tocris)
94
Tocris a2br antagonist 8
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
A2br Antagonist 8, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pm41115591-162-29-34
Average 94 stars, based on 1 article reviews
a2br antagonist 8 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
psb-603  (TargetMol)
93
TargetMol psb-603
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb 603, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB-603/targetmol___t23203
Average 93 stars, based on 1 article reviews
psb-603 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
psb 603  (TargetMol)
93
TargetMol psb 603
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb 603, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pm41033606-41-10-50
Average 93 stars, based on 1 article reviews
psb 603 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine  (Tocris)
94
Tocris chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Chlorophenzyl Piperazide 1 Sulfonyl Phenyl 1 Propylxanthine, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pm32271569__jm0c00235_si_001-5-37-40
Average 94 stars, based on 1 article reviews
chlorophenzyl piperazide 1 sulfonyl phenyl 1 propylxanthine - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
psb  (Tocris)
94
Tocris psb
Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C <t>),</t> <t>PSB-603</t> for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.
Psb, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psb-603/PSB+603/pm40583388-237-14-18
Average 94 stars, based on 1 article reviews
psb - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.

Journal: Scientific Reports

Article Title: Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies

doi: 10.1038/s41598-026-43642-1

Figure Lengend Snippet: Synergistic effect of dipyridamole and tucidinostat involves adenosine receptor activation. ( A ) MT-1 cells were treated with adenosine (250 µM), tucidinostat (Tuc; 360 nM), or their combination for 72 h. Cell viability was measured using the CCK-8 assay. Data are shown as means ± SD. *** p < 0.001, **** p < 0.0001. The synergy score was calculated using the SynergyFinder R package. (B-E) MT-1 cells were pretreated for 2 h with the indicated concentrations of selective adenosine receptor antagonists: DPCPX for A1 ( B ), ZM241385 for A2a ( C ), PSB-603 for A2b ( D ), or MRS1523 for A3 ( E ), followed by treatment with dipyridamole (Dip; 16 µM), tucidinostat (Tuc; 360 nM), or their combination for 48 h. Cell viability was assessed by CCK-8 assay. Data are presented as means ± SD. * p < 0.05, *** p < 0.001. Experiments were independently performed three times, and representative results are shown.

Article Snippet: DPCPX was purchased from Abcam, MRS1523 from Cayman Chemical Co. Ltd., and PSB-603 from MedChem Express.

Techniques: Activation Assay, CCK-8 Assay